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Changes in clinical manifestation of fibromyalgia
syndromes after Alzheimer’s disease diagnosis
Lloyd D. Hughes, MBChB
From East Practice Springfield Medical Centre, Arbroath, Scotland
ABSTRACT
Fibromyalgia syndrome (FMS) is defined by chronic widespread pain persisting for more than 3 months without an apparent
physical cause. The prevalence of FMS peaks between 50 and 70 years old, and it can be difficult to diagnose and treat due to
other comorbid conditions. Recent work has suggested that neurodegenerative conditions can be complicated by chronic pain.
This case study presents four patients with FMS residing in nursing homes. In all four cases, with the progression of Alzheimer’s
disease, patients saw improvements in pain syndromes, albeit to different degrees, and marked improvements in mobility. All
four patients also developed challenging behavioral and psychological symptoms of dementia requiring psychotropic prescriptions.
KEYWORDS Alzheimer’s dementia; chronic pain; fibromyalgia; nursing home
F
ibromyalgia syndrome (FMS), a condition of central
sensitization, is defined by chronic widespread pain,
stiffness of muscles and joints, and fatigue persisting
for >3 months without an apparent physical cause.1
Some individuals with FMS may have other unexplained
physical health symptoms, and there is evidence of
substantial psychiatric comorbidity.2 The prevalence of FMS
peaks between 50 and 70 years old,3 and the presentation
of FMS can be influenced by a wide variety of physical and
psychosocial factors.4 Recent work has suggested that
neurodegenerative conditions can be complicated by chronic
pain.5 This case series presents four patients with FMS
residing in a 44-bed nursing home and describes how the
diagnosis and progression of Alzheimer’s disease (AD)
affected the manifestation of their FMS.
CASE DESCRIPTIONS
Four patients, three women and one man, with confirmed
diagnoses of FMS predating a dementia diagnosis were admitted
to a nursing home where clinical care is provided by a general
practice team. All patients were admitted after family members
were unable to care for them at home due to AD progression.
Patients were diagnosed by a geriatric psychiatrist using the
International Classification of Disease–10 criteria.6 Diagnosis
involved clinical assessment and physical examination, in an out-
patient clinical setting or at home, alongside laboratory workup,
computed tomography, and formal cognitive testing.
Admissions occurred from January 2019 onwards.
Patient records were retrospectively reviewed for 12 months
from admission to the nursing home, and baseline character-
istics (age, gender, age at FMS and AD diagnoses, comorbid
diagnoses, and psychotropic medication prescriptions) were
recorded. All patients or their caregivers were informed of
the purpose of this retrospective analysis of case records and
consented to the information being used and published.
Psychotropic medications were recorded at the time of
admission and at death, using a standardized definition of
psychotropic medications.7 Table 1 summarizes pertinent
clinical characteristics and psychotropic prescriptions.
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For each patient, pain was assessed using the Pain
Assessment in Advanced Dementia,8 the widespread pain
index validated for FMS,9 and cognition was quantified
using the Six-Item Cognitive Impairment Test,10 with
nursing home care staff recording mobility assessments on
a quarterly basis in line with nursing home policy. Table 2
summarizes changes in these domains over time.
Alongside documented deterioration in cognition and
improvement in pain score and mobility, all four patients
developed challenging behavioral and psychological symp-
toms of dementia (BPSD). Case 1 developed a moderate to
severe depressive illness within 6 months of admission, with
marked anxiety disorder with insomnia. More broadly, there
were family concerns regarding apathy and social withdrawal.
These symptoms were managed with the introduction of
antidepressants, as well as anxiolytics with the support of the
local psychogeriatric community team. Regular input from
the community psychiatric nursing team was required to
engage with symptoms of severe anxiety disorder and panic
attacks. The family reported no premorbid psychi-
atric diagnoses.
Over the initial period of admission, Case 2’s depressive
disorder and insomnia deteriorated, which responded well to
an increase in her citalopram and change from melatonin to
trazodone. Nursing home staff voiced concerns about para-
noia of her food and tablets being poisoned in the absence of
delirium, but these responded with nondrug measures. Case
3 developed moderate to severe depressive disorder after
admission that responded well to alterations in her anti-
depressant medications. However, she developed delusions
regarding some staff at the nursing home leading to challeng-
ing and aggressive behavior; although this was generally man-
aged well with nondrug measures, lorazepam was required at
times. Case 4 also required upward titration of her anti-
depressant and addition of another agent to manage physical
symptoms associated with her depressive disorder.
For all patients, psychotropic prescribing was supported
by the primary care geriatric psychiatry liaison team, who
provided advice regarding medications to utilize for different
patients based upon their presentation and potential for iat-
rogenic harm.
DISCUSSION
This small case series has isolated two findings of inter-
est. First, in all four cases, with the progression of AD,
patients saw improvements in pain syndromes, albeit to
different degrees, and marked improvements in mobility.
It has been reported that patients with AD and chronic
pain are likely to feel diminishing levels of pain as a result
of cognitive decline.11 Generally, pain threshold tolerance
is increased with advancing AD, but the nature of this
relationship can be challenging to discern.12 A single case
study reported that a 71-year old woman with FMS and
AD noted improvements in FMS symptoms and mobility
with cognitive decline.13 A Japanese case series of seven
older patients with FMS and neurocognitive dysfunction,
which included single-photon emission computed tomog-
raphy imaging, found that central sensitization may be a
risk factor for widespread pain syndromes in older patients
with cognitive dysfunction.12 The relationship between
Table 1. Pertinent clinical characteristics of four patients




85 79 74 90
Gender Male Female Female Female
Age of FMS onset 67 70 65 75
Age of AD onset 82 75 72 85
Comorbidities COPD, diverticulitis, migraine,
osteoarthritis, BPH,
hypertension, pacemaker—
third-degree heart block, T2DM
Osteoarthritis, IHD, hypertension,
breast cancer (remission),











None Citalopram 10 mg OD; melatonin
4 mg Nocte
Zopiclone 15 mg Nocte Citalopram 10 mg OD;




Sertraline 100mg OD; zopiclone
3.75 mg Nocte; lorazepam
500 mcg BD; amitriptyline
10 mg Nocte
Trazodone 50 mg Nocte;
citalopram 30 mg OD
Citalopram 20 mg OD;
zopiclone 15 mg Nocte;
mirtazapine 30 mg Nocte;
lorazepam 500 mcg PRN up
to once daily for distress
Citalopram 30 mg OD;
mirtazapine 45 mg Nocte;
zopiclone 7.5 mg Nocte
AD indicates Alzheimer’s dementia; ARMD, age-related macular degeneration; BD, twice daily; BPH, benign prostatic hyperplasia; CKD, chronic kidney disease; COPD, chronic
obstructive pulmonary disease; FMS, fibromyalgia syndrome; IHD, ischemic heart disease; Nocte, at night; OD, once daily; PRN, as needed; T2DM, type 2 diabetes.
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the disease process of AD and its impact upon FMS
requires further review, in particular whether alterations
in pain and mobility are typical in this patient group and
the prevalence of FMS among older patients with cogni-
tive dysfunction.
Second, all four patients developed challenging BPSD
requiring psychotropic prescriptions. A systematic review
indicated that 82% of residents of nursing homes exhibited
at least one neuropsychiatric symptoms, with agitation and
apathy being most prevalent.14 General rates of psychiatric
diagnoses within the nursing home where all patients resided
were 14%, 6.8%, and 9% for pure depression, pure anxiety,
and mixed depression and anxiety disorder. This is in keep-
ing with internationally reported levels.15,16 However, the
symptoms experienced by these patients were marked, caused
considerable impact on quality of life, and required more sig-
nificant input in terms of drug and nondrug approaches
compared to those of other residents with the same psychi-
atric diagnoses. There is substantial lifetime psychiatric
comorbidity in individuals with fibromyalgia,2 with this
negatively impacting the severity and course of FMS,17 but
the nature of the relationship between FMS and BPSD, an
almost universal phenomenon in dementia,18 has not been
explored to date.
There are inherent limitations in extrapolating from
small case series without age-matched controls. More specif-
ically, the widespread pain index has not been validated in a
dementia population. In relation to the main findings of
reductions in pain and improvements in mobility, it could
be suggested that patients experienced less pain within the
nursing home environment than they did prior to admission.
However, this did not appear to be the case due to the level
of engagement within the nursing home and based on review
of admission reports.
This small case series has isolated that progressive demen-
tia syndromes may lead to improvements in pain experiences
with FMS, postulated to be related to damage to cerebral
structures and neuronal processing, alongside the potential
that FMS patients with dementia may experience trouble-
some BPSD. Within the locality, there are efforts to perform
prospective clinical research in this area to further interrogate
the nature of the relationship between FMS, BPSD, and AD
and to investigate the frequency of FMS in the elderly popu-
lation. More broadly, the relationship between patients with
FMS with preexisting psychiatric diagnoses and their risk of
developing dementia syndromes is being actively researched.
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